This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Outcome of Board meeting held on 12th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 3.6 pts more than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indrayani Biotech's board approved audited standalone results for Q4 and FY ended March 31, 2025, and accepted the resignation of Company Secretary V. Santhanakrishnan effective June 13, 2025 (he is moving to other opportunities). The consolidated results have been deferred to June 13. Full-year revenue from operations fell sharply to Rs 3,776.91 lakh from Rs 6,232.34 lakh last year, a drop of about 39%, though profit after tax was nearly flat at Rs 144.63 lakh vs Rs 145.74 lakh. Finance costs jumped to Rs 732.10 lakh from Rs 482.76 lakh (+52%), squeezing margins, and EPS dipped to Rs 0.32 from Rs 0.37. The statutory auditor (Venkatesh & Co) issued the report, but there is a notable contradiction: the company's filing says 'unmodified opinion' while the auditor's report text itself states it provides a basis for a 'qualified opinion' on the standalone results.
Sharply falling revenue combined with rising interest costs points to a tough year and likely pressure on the stock. The mismatch between the company claiming an unmodified audit opinion and the auditor's report text referencing a qualified opinion is a red flag investors should watch closely. Loss of the Company Secretary also adds minor governance uncertainty until a replacement is named.
| Q4 FY25 | Q4 FY24 | Change | |
|---|---|---|---|
| Revenue | ₹50.57 Cr | ₹44.38 Cr | +13.9% |
| Operating profit | −₹11.10 Cr | ₹3.70 Cr | −399.9% |
| Profit after tax | −₹8.53 Cr | ₹4.73 Cr | −280.1% |
| EBITDA margin | -11.3% | 22.9% | −34.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.